|Title:|| HIV protease inhibitors useful for the treatment of AIDS|
|Abstract:||Compounds of formula ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or optionally-substituted C.sub.1-4 alkyl or aryl, or R.sup.1 and R.sup.2 are joined together to form a monocyclic or bicyclic ring system, are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.|
|Inventor(s):|| Vacca; Joseph P. (Telford, PA), Dorsey; Bruce D. (Harleysville, PA), Guare; James P. (Quakertown, PA), Holloway; M. Katharine (Lansdale, PA), Hungate; Randall W. (Lansdale, PA), Levin; Rhonda B. (Lafayette Hill, PA) |
|Assignee:|| Merck & Co., Inc. (Rahway, NJ) |
|Filing Date:||Mar 21, 1995|
|Claims:||1. A composition, comprising a compound of the structure ##STR316## [Compound J,]3-([4,7-dichloro-1,3-benzoxazol-2-yl)methyl]amino)-5-ethyl-6-methylpyri din-2(1H)-one, and, optionally, AZT, or a pharmaceutically acceptable salt of any of the above. |
2. A composition, comprising a compound of the structure ##STR317## [Compound J] and AZT, or a pharmaceutically acceptable salt of any of the above.
3. A method of treating AIDS or HIV infection, comprising administering the pharmaceutical composition of claim 1 or 2.